Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

LLS And Forma Therapeutics to Collaborate

By Drug Discovery Trends Editor | March 17, 2010

The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics, Inc., announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.

This new collaboration expands upon the partnership formed between LLS and FORMA in July 2009. Taking an active role in the identification of novel therapies for patients, LLS has committed substantial, multi-year funding to support this collaboration as part of its Therapy Acceleration Program (TAP). TAP is LLS’s bold initiative designed to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers. By partnering directly with biotechnology companies, LLS is taking a results-oriented approach to more quickly identify potential breakthrough therapies and advance them along the FDA drug approval pathway.

B lymphocyte cells are an important component of the body’s immune system. B cells can become cancerous, leading to diseases such as non-Hodgkin’s lymphoma. Approximately 85 percent of non-Hodgkin’s lymphomas originate from B cells. Bcl-6 is a transcriptional repressor that down-regulates hundreds of genes important for control of function of normal and tumor cells. The project focuses on blocking Bcl-6 interaction with a protein co-repressor called SMRT. Inhibition of their binding provides an exciting new approach to treating lymphomas.

“With their oncology focus and unique drug discovery platform, FORMA has become an excellent partner for LLS. Together LLS and FORMA hope to change the standard of care and improve the quality of life for patients suffering from blood cancer,” said LLS CEO John Walter.

“FORMA is excited to be assisting LLS to achieve their mission to cure blood cancers. Our highly skilled team is dedicated to sharing our industry knowledge with LLS, leveraging our unique Computational Solvent (CS) Mapping technology to aid in structure-based drug design, screening and medicinal chemistry competence,” said FORMA CEO Steven Tregay, Ph.D.

Date: March 16, 2010
Source: Leukemia & Lymphoma Society


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE